PlainRecalls

Cyberonics, Inc

Compiled from official public sources by the publisher.

9 recalls on record · Latest: Jun 27, 2018

Subscribe to new Cyberonics, Inc recalls (RSS)

Agency notice ledger

Federal filing book Cyberonics, Inc LIGHT-BOOK · SINGLE-AGENCY

#1,588 of 14,151 · 9 notices · 0.009% archive

  • BOOK 9 notices
  • RANK #1,588 of 14,151
  • SHARE 0.009% archive
  • AGENCY FDA Devices (9)
  • CAT medical devices
  • CATS 1 category
  • LATEST Jun 27, 2018
  • PHOTO 3Cs Organics LLC

Nearest notice-volume peer: 3Cs Organics LLC (0 notice gap)

Cyberonics, Inc accounts for about 0.009% of the 104,423-notice archive on 9 distinct filings — a mid share signal beside absolute volume. FDA · CPSC · USDA FSIS · NHTSA notice stamps for this firm. Read with this firm → · Dominant category → · Similar-volume firm →

Where Cyberonics, Inc sits among 14,151 recalling firms

Cyberonics, Inc ranks 1,588th of 14,151 tracked firms by distinct recall-event count. Archive size reflects filing volume, not inherent product danger.

Cyberonics, Inc vs all firms by recall-notice count

Where this firm's archive sits among every tracked recalling manufacturer

9 1588th of 14151 higher than 12,464 of 14,151 firms

Firms, banded by distinct federal recall-event inventory

Each bar is a band; taller bars hold more firms. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source FDA · CPSC · USDA FSIS · NHTSA federal recall filings · 2026-09-13

Cyberonics, Inc in the notice-volume neighbourhood

Distinct federal recall events among this firm and nearest nationwide peers

notices

What this shows Cyberonics, Inc holds about 0.009% of archive notices alongside 9 distinct filings.

Source FDA · CPSC · USDA FSIS · NHTSA filings aggregated by PlainRecalls As of September 2026
FDA Devices Moderate Jun 27, 2018

VNS Therapy Programmer, Model 3000, v1.0 System
FDA Devices Moderate Feb 14, 2018

VNS(R) Therapy Programmer, GMDN: 44077, Model 3000 v1.0.2.2 Intended Use/Indications: United States Indications for Use: Epilepsy : The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. Depression : VNS Therapy is indicated for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age
FDA Devices Moderate Aug 23, 2017

VNS Therapy¿ AspireHC¿ Generator, VNS Therapy¿ AspireSR¿ Generator. Model No. 105. Product Usage: United States Indications for Use: Epilepsy (PMA 970003): The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications. Depression (PMA 970003/S050): VNS Therapy is indicated for the adjunctive long-term treatment of chronic or
FDA Devices Moderate Aug 23, 2017

VNS Therapy¿ AspireHC¿ Generator, VNS Therapy¿ AspireSR¿ Generator. Model No. 106. Product Usage: United States Indications for Use: Epilepsy (PMA 970003): The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications. Depression (PMA 970003/S050): VNS Therapy is indicated for the adjunctive long-term treatment of chronic or
FDA Devices Moderate Jan 27, 2016

VNS Therapy AspireSR Generator Model 106. Indicated for use as an adjunctive therapy in reducing the frequency of seizures.
FDA Devices Moderate Jan 27, 2016

Cyberonics Vagus Nerve Stimulator VNS Therapy AspireSR Generator, Model 106
FDA Devices Moderate Nov 25, 2015

Cyberonics Vagus Nerve Stimulator (VNS) Therapy AspireSR Generator, Model 106
FDA Devices Moderate May 6, 2015

VNS Therapy DemiPulse Generator Model 103 and VNS Therapy DemiPulse Duo Generator Model 104; CYBERONICS, INC.
FDA Devices Moderate Dec 31, 2014

Cyberonics VNS Therapy AspireHC, Model 105 Generator. The Cyberonics VNS Therapy System consists of the implantable VNS Therapy Generator, the VNS Therapy Lead, and the external programming system used to change the stimulation settings. Indicated for use as an adjunctive therapy in reducing the frequency of seizures.

Cyberonics, Inc holds a measurable archive slice

Drug and device firms outside this manufacturer and state, matched by notice volume and category footprint.

Frequently Asked Questions

How many federal recall notices name Cyberonics, Inc? ▼
PlainRecalls indexes 9 distinct federal recall events naming Cyberonics, Inc, aggregated from FDA, CPSC, USDA FSIS, and NHTSA filings (archive as of September 2026). That count is an issuance inventory, not a hazard score.
Where does Cyberonics, Inc sit among other recalling firms? ▼
Cyberonics, Inc ranks #1,588 of 14,151 by distinct recall-event count among 14,151 firms in this archive (88th percentile of firms with fewer notices). Rank tracks filing frequency, not product danger.
Which agency issues most of Cyberonics, Inc's notices? ▼
FDA Devices accounts for 9 of this firm's 9 indexed notices.
What product category dominates Cyberonics, Inc's filing book? ▼
Filings for Cyberonics, Inc span 1 product category, led by medical devices. Browse that category archive for peer firms and related notices.
Is a higher notice count more dangerous? ▼
No. Archive size reflects how often federal agencies publish recalls naming the firm — reporting volume, coverage, and product range all move the number. Always verify the individual notice with the issuing agency before acting on a specific product.
Cyberonics, Inc: 9 federal recall notices aggregated from FDA, CPSC, USDA FSIS, and NHTSA filings (lead agency FDA Devices). Verify individual notices with FDA directly before acting on a specific recall.

Firm-level totals aggregate distinct federal recall events naming Cyberonics, Inc; individual notices remain authoritative on each linked recall page.

Methodology · Corrections · FDA · CPSC · USDA FSIS · NHTSA · Archive as of September 2026